Genmab A/S Files Routine 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Aug 5, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, compliance, foreign-private-issuer
Related Tickers: GMAB
TL;DR
Genmab filed a standard 6-K, no new info, just compliance.
AI Summary
Genmab A/S filed a Form 6-K on August 5, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing is a routine report for a foreign private issuer and does not contain specific financial or operational updates for the month of August 2024.
Why It Matters
This filing serves as a notification to the SEC and investors that Genmab A/S is fulfilling its reporting obligations as a foreign private issuer. It ensures ongoing compliance and transparency.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material financial or operational information, thus posing minimal risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-010766 (filing_id) — Accession Number
- 20240805 (date) — Filing Date
- Form 6-K (document_type) — Filing Type
- Form S-8 (document_type) — Incorporated by Reference
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to report information as required by Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for the month of August 2024, and to be incorporated by reference into Genmab A/S's existing Form S-8 registration statements.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on August 5, 2024.
What is Genmab A/S's central index key (CIK)?
Genmab A/S's central index key is 0001434265.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive office is located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Does this filing contain specific financial results or operational updates for August 2024?
No, this Form 6-K is a routine report for a foreign private issuer and does not appear to contain specific financial results or operational updates for August 2024; it primarily serves to incorporate information into existing registration statements.
Filing Stats: 223 words · 1 min read · ~1 pages · Grade level 14.8 · Accepted 2024-08-05 06:28:32
Filing Documents
- tmb-20240805x6k.htm (6-K) — 18KB
- tmb-20240805xex99d1.htm (EX-99.1) — 27KB
- tmb-20240805xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-010766.txt ( ) — 53KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: August 5, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated August 5, 2024: Genmab Takes Full Control of Acasunlimab Development Program